Rosetta Genomics Loss Widens; Stock Down 7%

(RTTNews) - Israel-based Rosetta Genomics Ltd (ROSG), a developer of microRNA-based molecular diagnostics, Monday reported fourth-quarter net loss from continuing operations of $12.9 million or $1.34 per share for fiscal year 2013. This compares with a loss of $10.5 million or $2.35 per share a year ago.

Loss per share results for fiscal 2013 reflected a higher share count.

Excluding items, adjusted loss for the year was $12.1 million or $1.26 per share, compared with a loss of $7.7 million or $1.74 per share in the prior year.

On average, two analysts polled by Thomson Reuters estimated a loss of $0.50 per share for the quarter. Analysts' estimates typically exclude special items.

Revenues for the year were $405,000, up from $201,000 last year.

The company said the bottomline was impacted as it expended more on sales, marketing as well as research and development.

Rosetta stock closed Monday at $4.98, up $0.04 or 0.81%, on a volume of 725k shares on the Nasdaq. In after hours, the stock dropped $0.38 or 7.63% at $4.60.